James Crowe
Faculty Member
Last active: 7/27/2022


Dr. Crowe is Professor of Pediatrics, Pathology, Microbiology and Immunology, Ann Scott Carell Chair, and Director of the Vanderbilt Vaccine Center. His laboratory has a broad portfolio of work in the area of human immunology and immune repertoires, with an aim to discovery of mechanisms important to development of new vaccines. He has worked in East and West Africa, and has research collaborations ongoing with investigators in Uganda, Democratic Republic of the Congo, Nigeria, Sri Lanka, Chile and other international sites. He is the Director of the Human Immunome Project, an ambitious effort to identify the sequence of all transcripts for adaptive immune receptors on the planet.  He is an elected member of the National Academy of Medicine, the National Academy of Inventors, and has been the recipient of a number of major investigator awards for research, including the Harrington Prize for Innovation in Medicine, Stanley J. Korsmeyer of the ASCI, Judson Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, the E. Mead Johnson Award for Excellence in Pediatrics, the Outstanding Investigator Award of the American Federation for Medical Research, the Norman J. Siegel Award of the American Pediatric Society. He is an elected Fellow of AAM, AAAS, ASCI and AAP, IDSA, APS and others.


The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses. Martinez Viedma MDP, Kose N, Parham L, Balmaseda A, Kuan G, Lorenzana I, Harris E, Crowe JE, Pickett BE (2019) F1000Res : 1875
    › Primary publication · 32201571 (PubMed) · PMC7065662 (PubMed Central)
  2. E. coli production process yields stable dengue 1 virus-sized particles (VSPs). Hirsch J, Faber BW, Crowe JE, Verstrepen B, Cornelissen G (2020) Vaccine 38(17): 3305-3312
    › Primary publication · 32197924 (PubMed)
  3. Multi-state design of flexible proteins predicts sequences optimal for conformational change. Sauer MF, Sevy AM, Crowe JE, Meiler J (2020) PLoS Comput Biol 16(2): e1007339
    › Primary publication · 32032348 (PubMed) · PMC7032724 (PubMed Central)
  4. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization. Gilchuk P, Murin CD, Milligan JC, Cross RW, Mire CE, Ilinykh PA, Huang K, Kuzmina N, Altman PX, Hui S, Gunn BM, Bryan AL, Davidson E, Doranz BJ, Turner HL, Alkutkar T, Flinko R, Orlandi C, Carnahan R, Nargi R, Bombardi RG, Vodzak ME, Li S, Okoli A, Ibeawuchi M, Ohiaeri B, Lewis GK, Alter G, Bukreyev A, Saphire EO, Geisbert TW, Ward AB, Crowe JE (2020) Immunity 52(2): 388-403.e12
    › Primary publication · 32023489 (PubMed) · PMC7111202 (PubMed Central)
  5. Correction: Tissue-Specific Expressed Antibody Variable Gene Repertoires. Briney BS, Willis JR, Finn JA, McKinney BA, Crowe JE (2020) PLoS One 15(1): e0228412
    › Primary publication · 31978140 (PubMed) · PMC6980481 (PubMed Central)
  6. Broad dengue neutralization in mosquitoes expressing an engineered antibody. Buchman A, Gamez S, Li M, Antoshechkin I, Li HH, Wang HW, Chen CH, Klein MJ, Duchemin JB, Crowe JE, Paradkar PN, Akbari OS (2020) PLoS Pathog 16(1): e1008103
    › Primary publication · 31945137 (PubMed) · PMC6964813 (PubMed Central)
  7. Immune repertoire fingerprinting by principal component analysis reveals shared features in subject groups with common exposures. Sevy AM, Soto C, Bombardi RG, Meiler J, Crowe JE (2019) BMC Bioinformatics 20(1): 629
    › Primary publication · 31801472 (PubMed) · PMC6894320 (PubMed Central)
  8. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge. Zhao H, Xu L, Bombardi R, Nargi R, Deng Z, Errico JM, Nelson CA, Dowd KA, Pierson TC, Crowe JE, Diamond MS, Fremont DH (2020) J Exp Med 217(2)
    › Primary publication · 31757867 (PubMed) · PMC7041715 (PubMed Central)
  9. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice. Gilchuk IM, Bangaru S, Gilchuk P, Irving RP, Kose N, Bombardi RG, Thornburg NJ, Creech CB, Edwards KM, Li S, Turner HL, Yu W, Zhu X, Wilson IA, Ward AB, Crowe JE (2019) Cell Host Microbe 26(6): 715-728.e8
    › Primary publication · 31757769 (PubMed) · PMC6941661 (PubMed Central)
  10. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Zhu X, Turner HL, Lang S, McBride R, Bangaru S, Gilchuk IM, Yu W, Paulson JC, Crowe JE, Ward AB, Wilson IA (2019) Cell Host Microbe 26(6): 729-738.e4
    › Primary publication · 31757767 (PubMed) · PMC6908751 (PubMed Central)
  11. Vaccine innovations for emerging infectious diseases-a symposium report. Cable J, Srikantiah P, Crowe JE, Pulendran B, Hill A, Ginsberg A, Koff W, Mathew A, Ng T, Jansen K, Glenn G, Permar S, Wilson I, Weiner DB, Weissman D, Rappuoli R (2020) Ann N Y Acad Sci 1462(1): 14-26
    › Primary publication · 31659752 (PubMed)
  12. High frequency of shared clonotypes in human B cell receptor repertoires. Soto C, Bombardi RG, Branchizio A, Kose N, Matta P, Sevy AM, Sinkovits RS, Gilchuk P, Finn JA, Crowe JE (2019) Nature 566(7744): 398-402
    › Primary publication · 30760926 (PubMed) · PMC6949180 (PubMed Central)
  13. New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications. Engelhardt BG, Savani U, Jung DK, Powers AC, Jagasia M, Chen H, Winnick JJ, Tamboli RA, Crowe JE, Abumrad NN (2019) Biol Blood Marrow Transplant 25(6): 1225-1231
    › Primary publication · 30738170 (PubMed) · PMC6559863 (PubMed Central)
  14. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection. Williamson LE, Flyak AI, Kose N, Bombardi R, Branchizio A, Reddy S, Davidson E, Doranz BJ, Fusco ML, Saphire EO, Halfmann PJ, Kawaoka Y, Piper AE, Glass PJ, Crowe JE (2019) J Virol 93(8)
    › Primary publication · 30728263 (PubMed) · PMC6450119 (PubMed Central)
  15. Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice. Salazar V, Jagger BW, Mongkolsapaya J, Burgomaster KE, Dejnirattisai W, Winkler ES, Fernandez E, Nelson CA, Fremont DH, Pierson TC, Crowe JE, Screaton GR, Diamond MS (2019) Cell Rep 26(6): 1585-1597.e4
    › Primary publication · 30726740 (PubMed) · PMC6420780 (PubMed Central)
  16. Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains. Turner HL, Pallesen J, Lang S, Bangaru S, Urata S, Li S, Cottrell CA, Bowman CA, Crowe JE, Wilson IA, Ward AB (2019) PLoS Biol 17(2): e3000139
    › Primary publication · 30716060 (PubMed) · PMC6375650 (PubMed Central)
  17. Antibody Determinants of Influenza Immunity. Crowe JE (2019) J Infect Dis 219(Suppl_1): S21-S29
    › Primary publication · 30715373 (PubMed) · PMC6452307 (PubMed Central)
  18. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope. Long F, Doyle M, Fernandez E, Miller AS, Klose T, Sevvana M, Bryan A, Davidson E, Doranz BJ, Kuhn RJ, Diamond MS, Crowe JE, Rossmann MG (2019) Proc Natl Acad Sci U S A 116(5): 1591-1596
    › Primary publication · 30642974 (PubMed) · PMC6358714 (PubMed Central)
  19. Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses. Sevy AM, Wu NC, Gilchuk IM, Parrish EH, Burger S, Yousif D, Nagel MBM, Schey KL, Wilson IA, Crowe JE, Meiler J (2019) Proc Natl Acad Sci U S A 116(5): 1597-1602
    › Primary publication · 30642961 (PubMed) · PMC6358683 (PubMed Central)
  20. Influenza Virus-Specific Human Antibody Repertoire Studies. Crowe JE (2019) J Immunol 202(2): 368-373
    › Primary publication · 30617118 (PubMed) · PMC6327975 (PubMed Central)
  21. Current Understanding of Humoral Immunity to Enterovirus D68. Vogt MR, Crowe JE (2018) J Pediatric Infect Dis Soc 7(suppl_2): S49-S53
    › Primary publication · 30590621 (PubMed)
  22. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth. Chukwuma VU, Kose N, Sather DN, Sapparapu G, Falk R, King H, Singh V, Lampley R, Malherbe DC, Ditto NT, Sullivan JT, Barnes T, Doranz BJ, Labranche CC, Montefiori DC, Kalams SA, Haigwood NL, Crowe JE (2018) PLoS One 13(12): e0209437
    › Primary publication · 30566528 (PubMed) · PMC6300260 (PubMed Central)
  23. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine. Kimble JB, Malherbe DC, Meyer M, Gunn BM, Karim MM, Ilinykh PA, Iampietro M, Mohamed KS, Negi S, Gilchuk P, Huang K, Wolf YI, Braun W, Crowe JE, Alter G, Bukreyev A (2019) J Virol 93(4)
    › Primary publication · 30518655 (PubMed) · PMC6364037 (PubMed Central)
  24. Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms. Bennett MR, Bombardi RG, Kose N, Parrish EH, Nagel MB, Petit RA, Read TD, Schey KL, Thomsen IP, Skaar EP, Crowe JE (2019) J Infect Dis 219(8): 1264-1273
    › Primary publication · 30496483 (PubMed) · PMC6452300 (PubMed Central)
  25. Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody. Wirawan M, Fibriansah G, Marzinek JK, Lim XX, Ng TS, Sim AYL, Zhang Q, Kostyuchenko VA, Shi J, Smith SA, Verma CS, Anand G, Crowe JE, Bond PJ, Lok SM (2019) Structure 27(2): 253-267.e8
    › Primary publication · 30471923 (PubMed) · PMC6365167 (PubMed Central)
  26. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions. Goo L, Debbink K, Kose N, Sapparapu G, Doyle MP, Wessel AW, Richner JM, Burgomaster KE, Larman BC, Dowd KA, Diamond MS, Crowe JE, Pierson TC (2019) Nat Microbiol 4(1): 71-77
    › Primary publication · 30455471 (PubMed) · PMC6435290 (PubMed Central)
  27. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein. Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE, Slifka MK, Fremont DH, Klimstra WB, Diamond MS (2019) Nat Microbiol 4(1): 187-197
    › Primary publication · 30455470 (PubMed) · PMC6294662 (PubMed Central)
  28. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. Kinchen VJ, Zahid MN, Flyak AI, Soliman MG, Learn GH, Wang S, Davidson E, Doranz BJ, Ray SC, Cox AL, Crowe JE, Bjorkman PJ, Shaw GM, Bailey JR (2018) Cell Host Microbe 24(5): 717-730.e5
    › Primary publication · 30439341 (PubMed) · PMC6250073 (PubMed Central)
  29. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE, Bailey JR, Bjorkman PJ (2018) Cell Host Microbe 24(5): 703-716.e3
    › Primary publication · 30439340 (PubMed) · PMC6258177 (PubMed Central)
  30. In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model. Patel A, Park DH, Davis CW, Smith TRF, Leung A, Tierney K, Bryan A, Davidson E, Yu X, Racine T, Reed C, Gorman ME, Wise MC, Elliott STC, Esquivel R, Yan J, Chen J, Muthumani K, Doranz BJ, Saphire EO, Crowe JE, Broderick KE, Kobinger GP, He S, Qiu X, Kobasa D, Humeau L, Sardesai NY, Ahmed R, Weiner DB (2018) Cell Rep 25(7): 1982-1993.e4
    › Primary publication · 30428362 (PubMed) · PMC6319964 (PubMed Central)
  31. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, Screaton G, Crowe JE, Wang WK (2018) J Virol 92(23)
    › Primary publication · 30185598 (PubMed) · PMC6232466 (PubMed Central)
  32. Integrating linear optimization with structural modeling to increase HIV neutralization breadth. Sevy AM, Panda S, Crowe JE, Meiler J, Vorobeychik Y (2018) PLoS Comput Biol 14(2): e1005999
    › Primary publication · 29451898 (PubMed) · PMC5833279 (PubMed Central)
  33. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms. Mankowski MC, Kinchen VJ, Wasilewski LN, Flyak AI, Ray SC, Crowe JE, Bailey JR (2018) Proc Natl Acad Sci U S A 115(1): E82-E91
    › Primary publication · 29255018 (PubMed) · PMC5776832 (PubMed Central)
  34. Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein. Sangha AK, Dong J, Williamson L, Hashiguchi T, Saphire EO, Crowe JE, Meiler J (2017) Structure 25(12): 1820-1828.e2
    › Primary publication · 29153506 (PubMed) · PMC5718948 (PubMed Central)
  35. Structure-function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8. Matho MH, Schlossman A, Gilchuk IM, Miller G, Mikulski Z, Hupfer M, Wang J, Bitra A, Meng X, Xiang Y, Kaever T, Doukov T, Ley K, Crotty S, Peters B, Hsieh-Wilson LC, Crowe JE, Zajonc DM (2018) J Biol Chem 293(1): 390-401
    › Primary publication · 29123031 (PubMed) · PMC5766908 (PubMed Central)
  36. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans. Grifoni A, Pham J, Sidney J, O'Rourke PH, Paul S, Peters B, Martini SR, de Silva AD, Ricciardi MJ, Magnani DM, Silveira CGT, Maestri A, Costa PR, de-Oliveira-Pinto LM, de Azeredo EL, Damasco PV, Phillips E, Mallal S, de Silva AM, Collins M, Durbin A, Diehl SA, Cerpas C, Balmaseda A, Kuan G, Coloma J, Harris E, Crowe JE, Stone M, Norris PJ, Busch M, Vivanco-Cid H, Cox J, Graham BS, Ledgerwood JE, Turtle L, Solomon T, Kallas EG, Watkins DI, Weiskopf D, Sette A (2017) J Virol 91(24)
    › Primary publication · 28978707 (PubMed) · PMC5709580 (PubMed Central)
  37. Epitope and Paratope Mapping Reveals Temperature-Dependent Alterations in the Dengue-Antibody Interface. Lim XX, Chandramohan A, Lim XE, Crowe JE, Lok SM, Anand GS (2017) Structure 25(9): 1391-1402.e3
    › Primary publication · 28823471 (PubMed)
  38. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design. Crowe JE (2017) Cell Host Microbe 22(2): 193-206
    › Primary publication · 28799905 (PubMed) · PMC5700460 (PubMed Central)
  39. Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine. Crowe JE (2018) Cold Spring Harb Perspect Biol 10(7)
    › Primary publication · 28663208 (PubMed) · PMC5829045 (PubMed Central)
  40. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, Smith PP, Denton M, Corvey C, Krishnan S, Colgin LMA, Ducore RM, Lewis AD, Axthelm MK, Mandron M, Cortez P, Rothblatt J, Rao E, Focken I, Carter K, Sapparapau G, Crowe JE, Diamond MS, Streblow DN (2017) PLoS Negl Trop Dis 11(6): e0005637
    › Primary publication · 28628616 (PubMed) · PMC5491320 (PubMed Central)
  41. Treating Flu with Skin of Frog. Crowe JE (2017) Immunity 46(4): 517-518
    › Primary publication · 28423328 (PubMed)
  42. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Mire CE, Geisbert JB, Borisevich V, Fenton KA, Agans KN, Flyak AI, Deer DJ, Steinkellner H, Bohorov O, Bohorova N, Goodman C, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Crowe JE, Zeitlin L, Geisbert TW (2017) Sci Transl Med 9(384)
    › Primary publication · 28381540 (PubMed) · PMC5719873 (PubMed Central)
  43. A human antibody against Zika virus crosslinks the E protein to prevent infection. Hasan SS, Miller A, Sapparapu G, Fernandez E, Klose T, Long F, Fokine A, Porta JC, Jiang W, Diamond MS, Crowe JE, Kuhn RJ, Rossmann MG (2017) Nat Commun : 14722
    › Primary publication · 28300075 (PubMed) · PMC5356071 (PubMed Central)
  44. Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action. Thomsen IP, Sapparapu G, James DBA, Cassat JE, Nagarsheth M, Kose N, Putnam N, Boguslawski KM, Jones LS, Wood JB, Creech CB, Torres VJ, Crowe JE (2017) J Infect Dis 215(7): 1124-1131
    › Primary publication · 28186295 (PubMed) · PMC5426380 (PubMed Central)
  45. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Miner JJ, Cook LE, Hong JP, Smith AM, Richner JM, Shimak RM, Young AR, Monte K, Poddar S, Crowe JE, Lenschow DJ, Diamond MS (2017) Sci Transl Med 9(375)
    › Primary publication · 28148840 (PubMed) · PMC5448557 (PubMed Central)
  46. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE (2017) Nat Microbiol : 16271
    › Primary publication · 28134924 (PubMed) · PMC5463187 (PubMed Central)
  47. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Wen X, Mousa JJ, Bates JT, Lamb RA, Crowe JE, Jardetzky TS (2017) Nat Microbiol : 16272
    › Primary publication · 28134915 (PubMed) · PMC5308794 (PubMed Central)
  48. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination. Nivarthi UK, Kose N, Sapparapu G, Widman D, Gallichotte E, Pfaff JM, Doranz BJ, Weiskopf D, Sette A, Durbin AP, Whitehead SS, Baric R, Crowe JE, de Silva AM (2017) J Virol 91(5)
    › Primary publication · 28031369 (PubMed) · PMC5309932 (PubMed Central)
  49. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Sapparapu G, Fernandez E, Kose N, Bin Cao , Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE (2016) Nature 540(7633): 443-447
    › Primary publication · 27819683 (PubMed) · PMC5583716 (PubMed Central)
  50. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113(44): E6849-E6858
    › Primary publication · 27791117 (PubMed) · PMC5098655 (PubMed Central)
  51. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections. Gilchuk I, Gilchuk P, Sapparapu G, Lampley R, Singh V, Kose N, Blum DL, Hughes LJ, Satheshkumar PS, Townsend MB, Kondas AV, Reed Z, Weiner Z, Olson VA, Hammarlund E, Raue HP, Slifka MK, Slaughter JC, Graham BS, Edwards KM, Eisenberg RJ, Cohen GH, Joyce S, Crowe JE (2016) Cell 167(3): 684-694.e9
    › Primary publication · 27768891 (PubMed) · PMC5093772 (PubMed Central)
  52. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Shanker S, Czakó R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE, Estes MK, Prasad BV (2016) Proc Natl Acad Sci U S A 113(40): E5830-E5837
    › Primary publication · 27647885 (PubMed) · PMC5056091 (PubMed Central)
  53. Teaching a Clone to Walk, One Step at a Time. Crowe JE (2016) Cell 166(6): 1360-1361
    › Primary publication · 27610559 (PubMed)
  54. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses. Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE, Aman MJ, Dye JM, Lai JR, Chandran K (2016) Science 354(6310): 350-354
    › Primary publication · 27608667 (PubMed) · PMC5647781 (PubMed Central)
  55. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Pallesen J, Murin CD, de Val N, Cottrell CA, Hastie KM, Turner HL, Fusco ML, Flyak AI, Zeitlin L, Crowe JE, Andersen KG, Saphire EO, Ward AB (2016) Nat Microbiol 1(9): 16128
    › Primary publication · 27562261 (PubMed) · PMC5003320 (PubMed Central)
  56. Phenome-Wide Association Study to Explore Relationships between Immune System Related Genetic Loci and Complex Traits and Diseases. Verma A, Basile AO, Bradford Y, Kuivaniemi H, Tromp G, Carey D, Gerhard GS, Crowe JE, Ritchie MD, Pendergrass SA (2016) PLoS One 11(8): e0160573
    › Primary publication · 27508393 (PubMed) · PMC4980020 (PubMed Central)
  57. Recognition of influenza H3N2 variant virus by human neutralizing antibodies. Bangaru S, Nieusma T, Kose N, Thornburg NJ, Finn JA, Kaplan BS, King HG, Singh V, Lampley RM, Sapparapu G, Cisneros A, Edwards KM, Slaughter JC, Edupuganti S, Lai L, Richt JA, Webby RJ, Ward AB, Crowe JE (2016) JCI Insight 1(10)
    › Primary publication · 27482543 (PubMed) · PMC4962875 (PubMed Central)
  58. Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique. Alvarado G, Crowe JE (2016) Methods Mol Biol : 63-76
    › Primary publication · 27464688 (PubMed)
  59. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE, Dermody TS, Diamond MS, Morrison TE (2016) Cell Rep 16(5): 1326-1338
    › Primary publication · 27452455 (PubMed) · PMC5003573 (PubMed Central)
  60. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein. Hicar MD, Chen X, Sulli C, Barnes T, Goodman J, Sojar H, Briney B, Willis J, Chukwuma VU, Kalams SA, Doranz BJ, Spearman P, Crowe JE (2016) PLoS One 11(7): e0158861
    › Primary publication · 27411063 (PubMed) · PMC4943599 (PubMed Central)
  61. Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6. Cho MJ, Ellebrecht CT, Hammers CM, Mukherjee EM, Sapparapu G, Boudreaux CE, McDonald SM, Crowe JE, Payne AS (2016) J Immunol 197(4): 1065-73
    › Primary publication · 27402694 (PubMed) · PMC4976025 (PubMed Central)
  62. Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding. Sapparapu G, Czakó R, Alvarado G, Shanker S, Prasad BV, Atmar RL, Estes MK, Crowe JE (2016) PLoS Pathog 12(6): e1005719
    › Primary publication · 27355511 (PubMed) · PMC4927092 (PubMed Central)
  63. Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1. Boehme KW, Ikizler M, Iskarpatyoti JA, Wetzel JD, Willis J, Crowe JE, LaBranche CC, Montefiori DC, Wilson GJ, Dermody TS (2016) mSphere 1(3)
    › Primary publication · 27303748 (PubMed) · PMC4888892 (PubMed Central)
  64. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV. Wen X, Pickens J, Mousa JJ, Leser GP, Lamb RA, Crowe JE, Jardetzky TS (2016) PLoS One 11(5): e0155917
    › Primary publication · 27224013 (PubMed) · PMC4880302 (PubMed Central)
  65. Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints. Finn JA, Koehler Leman J, Willis JR, Cisneros A, Crowe JE, Meiler J (2016) PLoS One 11(5): e0154811
    › Primary publication · 27182833 (PubMed) · PMC4868311 (PubMed Central)
  66. Deep sequencing and human antibody repertoire analysis. Boyd SD, Crowe JE (2016) Curr Opin Immunol : 103-9
    › Primary publication · 27065089 (PubMed) · PMC5203765 (PubMed Central)
  67. Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells. Clark KB, Hsiao HM, Bassit L, Crowe JE, Schinazi RF, Perng GC, Villinger F (2016) Virology : 162-72
    › Primary publication · 27058763 (PubMed) · PMC5538722 (PubMed Central)
  68. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Willis JR, Finn JA, Briney B, Sapparapu G, Singh V, King H, LaBranche CC, Montefiori DC, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113(16): 4446-51
    › Primary publication · 27044078 (PubMed) · PMC4843476 (PubMed Central)
  69. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. Messer WB, Yount BL, Royal SR, de Alwis R, Widman DG, Smith SA, Crowe JE, Pfaff JM, Kahle KM, Doranz BJ, Ibarra KD, Harris E, de Silva AM, Baric RS (2016) J Virol 90(10): 5090-5097
    › Primary publication · 26962223 (PubMed) · PMC4859728 (PubMed Central)
  70. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations. Thornburg NJ, Zhang H, Bangaru S, Sapparapu G, Kose N, Lampley RM, Bombardi RG, Yu Y, Graham S, Branchizio A, Yoder SM, Rock MT, Creech CB, Edwards KM, Lee D, Li S, Wilson IA, García-Sastre A, Albrecht RA, Crowe JE (2016) J Clin Invest 126(4): 1482-94
    › Primary publication · 26950424 (PubMed) · PMC4811156 (PubMed Central)
  71. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies. Bornholdt ZA, Ndungo E, Fusco ML, Bale S, Flyak AI, Crowe JE, Chandran K, Saphire EO (2016) mBio 7(1): e02154-15
    › Primary publication · 26908579 (PubMed) · PMC4791852 (PubMed Central)
  72. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies. Ilinykh PA, Shen X, Flyak AI, Kuzmina N, Ksiazek TG, Crowe JE, Bukreyev A (2016) J Virol 90(8): 3890-3901
    › Primary publication · 26819310 (PubMed) · PMC4810552 (PubMed Central)
  73. Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation. Engelhardt BG, Paczesny S, Jung DK, Daguindau E, Jagasia M, Savani BN, Chinratanalab W, Cornell RF, Goodman S, Greer JP, Kassim AA, Sengsayadeth S, Yoder SM, Rock MT, Crowe JE (2016) Haematologica 101(5): e204-8
    › Primary publication · 26819055 (PubMed) · PMC5004357 (PubMed Central)
  74. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection. Flyak AI, Shen X, Murin CD, Turner HL, David JA, Fusco ML, Lampley R, Kose N, Ilinykh PA, Kuzmina N, Branchizio A, King H, Brown L, Bryan C, Davidson E, Doranz BJ, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Saphire EO, Ward AB, Bukreyev A, Crowe JE (2016) Cell 164(3): 392-405
    › Primary publication · 26806128 (PubMed) · PMC4733404 (PubMed Central)
  75. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE (2016) Vaccine 34(7): 950-6
    › Primary publication · 26772634 (PubMed) · PMC4731299 (PubMed Central)
  76. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE (2016) Mol Immunol : 94-103
    › Primary publication · 26748387 (PubMed) · PMC4762738 (PubMed Central)
  77. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS (2015) Cell 163(5): 1095-1107
    › Primary publication · 26553503 (PubMed) · PMC4659373 (PubMed Central)
  78. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site. Smith SA, Nivarthi UK, de Alwis R, Kose N, Sapparapu G, Bombardi R, Kahle KM, Pfaff JM, Lieberman S, Doranz BJ, de Silva AM, Crowe JE (2016) J Virol 90(2): 780-9
    › Primary publication · 26512092 (PubMed) · PMC4702676 (PubMed Central)
  79. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE, Diamond MS, Rossmann MG (2015) Proc Natl Acad Sci U S A 112(45): 13898-903
    › Primary publication · 26504196 (PubMed) · PMC4653152 (PubMed Central)
  80. Deciphering the human immunome. Crowe JE, Koff WC (2015) Expert Rev Vaccines 14(11): 1421-5
    › Primary publication · 26485213 (PubMed)
  81. A new quaternary structure epitope on dengue virus serotype 2 is the target of durable type-specific neutralizing antibodies. Gallichotte EN, Widman DG, Yount BL, Wahala WM, Durbin A, Whitehead S, Sariol CA, Crowe JE, de Silva AM, Baric RS (2015) mBio 6(5): e01461-15
    › Primary publication · 26463165 (PubMed) · PMC4620467 (PubMed Central)
  82. Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model. Callaway JB, Smith SA, Widman DG, McKinnon KP, Scholle F, Sempowski GD, Dittmer DP, Crowe JE, de Silva AM, Ting JP (2015) PLoS One 10(8): e0136708
    › Primary publication · 26301593 (PubMed) · PMC4547738 (PubMed Central)
  83. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. Chukwuma VU, Hicar MD, Chen X, Nicholas KJ, Joyner A, Kalams SA, Landucci G, Forthal DN, Spearman PW, Crowe JE (2015) PLoS One 10(7): e0133509
    › Primary publication · 26226263 (PubMed) · PMC4520566 (PubMed Central)
  84. Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites. Winarski KL, Thornburg NJ, Yu Y, Sapparapu G, Crowe JE, Spiller BW (2015) Proc Natl Acad Sci U S A 112(30): 9346-51
    › Primary publication · 26170302 (PubMed) · PMC4522792 (PubMed Central)
  85. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Khomadiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE (2015) Cell Host Microbe 18(1): 86-95
    › Primary publication · 26159721 (PubMed) · PMC4501771 (PubMed Central)
  86. Design of Protein Multi-specificity Using an Independent Sequence Search Reduces the Barrier to Low Energy Sequences. Sevy AM, Jacobs TM, Crowe JE, Meiler J (2015) PLoS Comput Biol 11(7): e1004300
    › Primary publication · 26147100 (PubMed) · PMC4493036 (PubMed Central)
  87. DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Fibriansah G, Ibarra KD, Ng TS, Smith SA, Tan JL, Lim XN, Ooi JS, Kostyuchenko VA, Wang J, de Silva AM, Harris E, Crowe JE, Lok SM (2015) Science 349(6243): 88-91
    › Primary publication · 26138979 (PubMed) · PMC4672004 (PubMed Central)
  88. Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies. Smith SA, Crowe JE (2015) Microbiol Spectr 3(1): AID-0027-2014
    › Primary publication · 26104564 (PubMed) · PMC8162739 (PubMed Central)
  89. Committing the Oldest Sins in the Newest Kind of Ways-Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head. Krause JC, Crowe JE (2014) Microbiol Spectr 2(5)
    › Primary publication · 26104373 (PubMed)
  90. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection. Callaway JB, Smith SA, McKinnon KP, de Silva AM, Crowe JE, Ting JP (2015) J Biol Chem 290(28): 17306-20
    › Primary publication · 26032420 (PubMed) · PMC4498069 (PubMed Central)
  91. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. Willis JR, Sapparapu G, Murrell S, Julien JP, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE (2015) J Clin Invest 125(6): 2523-31
    › Primary publication · 25985274 (PubMed) · PMC4497764 (PubMed Central)
  92. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Hashiguchi T, Fusco ML, Bornholdt ZA, Lee JE, Flyak AI, Matsuoka R, Kohda D, Yanagi Y, Hammel M, Crowe JE, Saphire EO (2015) Cell 160(5): 904-912
    › Primary publication · 25723165 (PubMed) · PMC4344967 (PubMed Central)
  93. Mechanism of human antibody-mediated neutralization of Marburg virus. Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, Klages C, Ksiazek TG, Ward AB, Saphire EO, Bukreyev A, Crowe JE (2015) Cell 160(5): 893-903
    › Primary publication · 25723164 (PubMed) · PMC4344968 (PubMed Central)
  94. Challenges and opportunities in developing respiratory syncytial virus therapeutics. Simões EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ (2015) J Infect Dis : S1-S20
    › Primary publication · 25713060 (PubMed) · PMC4345819 (PubMed Central)
  95. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Fibriansah G, Tan JL, Smith SA, de Alwis R, Ng TS, Kostyuchenko VA, Jadi RS, Kukkaro P, de Silva AM, Crowe JE, Lok SM (2015) Nat Commun : 6341
    › Primary publication · 25698059 (PubMed) · PMC4346626 (PubMed Central)
  96. Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. Hooper KA, Crowe JE, Bloom JD (2015) J Virol 89(7): 3737-45
    › Primary publication · 25609803 (PubMed) · PMC4403400 (PubMed Central)
  97. Identification of residues in the human respiratory syncytial virus fusion protein that modulate fusion activity and pathogenesis. Hotard AL, Lee S, Currier MG, Crowe JE, Sakamoto K, Newcomb DC, Peebles RS, Plemper RK, Moore ML (2015) J Virol 89(1): 512-22
    › Primary publication · 25339762 (PubMed) · PMC4301159 (PubMed Central)
  98. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. de Alwis R, Williams KL, Schmid MA, Lai CY, Patel B, Smith SA, Crowe JE, Wang WK, Harris E, de Silva AM (2014) PLoS Pathog 10(10): e1004386
    › Primary publication · 25275316 (PubMed) · PMC4183589 (PubMed Central)
  99. Isolation of dengue virus-specific memory B cells with live virus antigen from human subjects following natural infection reveals the presence of diverse novel functional groups of antibody clones. Smith SA, de Alwis AR, Kose N, Jadi RS, de Silva AM, Crowe JE (2014) J Virol 88(21): 12233-41
    › Primary publication · 25100837 (PubMed) · PMC4248927 (PubMed Central)
  100. Tissue-specific expressed antibody variable gene repertoires. Briney BS, Willis JR, Finn JA, McKinney BA, Crowe JE (2014) PLoS One 9(6): e100839
    › Primary publication · 24956460 (PubMed) · PMC4067404 (PubMed Central)
  101. STAT4 deficiency fails to induce lung Th2 or Th17 immunity following primary or secondary respiratory syncytial virus (RSV) challenge but enhances the lung RSV-specific CD8+ T cell immune response to secondary challenge. Dulek DE, Newcomb DC, Toki S, Goliniewska K, Cephus J, Reiss S, Bates JT, Crowe JE, Boyd KL, Moore ML, Zhou W, Peebles RS (2014) J Virol 88(17): 9655-72
    › Primary publication · 24920804 (PubMed) · PMC4136353 (PubMed Central)
  102. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE (2014) Virology : 139-44
    › Primary publication · 24725940 (PubMed) · PMC4004766 (PubMed Central)
  103. Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA. Almagro JC, Gilliland GL, Breden F, Scott JK, Sok D, Pauthner M, Reichert JM, Helguera G, Andrabi R, Mabry R, Bléry M, Voss JE, Laurén J, Abuqayyas L, Barghorn S, Ben-Jacob E, Crowe JE, Huston JS, Johnston SA, Krauland E, Lund-Johansen F, Marasco WA, Parren PW, Xu KY (2014) MAbs 6(3): 577-618
    › Primary publication · 24589717 (PubMed) · PMC4011904 (PubMed Central)
  104. Proof of principle for epitope-focused vaccine design. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, Rupert P, Correnti C, Kalyuzhniy O, Vittal V, Connell MJ, Stevens E, Schroeter A, Chen M, Macpherson S, Serra AM, Adachi Y, Holmes MA, Li Y, Klevit RE, Graham BS, Wyatt RT, Baker D, Strong RK, Crowe JE, Johnson PR, Schief WR (2014) Nature 507(7491): 201-6
    › Primary publication · 24499818 (PubMed) · PMC4260937 (PubMed Central)
  105. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. Fibriansah G, Tan JL, Smith SA, de Alwis AR, Ng TS, Kostyuchenko VA, Ibarra KD, Wang J, Harris E, de Silva A, Crowe JE, Lok SM (2014) EMBO Mol Med 6(3): 358-71
    › Primary publication · 24421336 (PubMed) · PMC3958310 (PubMed Central)
  106. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Messer WB, de Alwis R, Yount BL, Royal SR, Huynh JP, Smith SA, Crowe JE, Doranz BJ, Kahle KM, Pfaff JM, White LJ, Sariol CA, de Silva AM, Baric RS (2014) Proc Natl Acad Sci U S A 111(5): 1939-44
    › Primary publication · 24385585 (PubMed) · PMC3918811 (PubMed Central)
  107. Combining single RNA sensitive probes with subdiffraction-limited and live-cell imaging enables the characterization of virus dynamics in cells. Alonas E, Lifland AW, Gudheti M, Vanover D, Jung J, Zurla C, Kirschman J, Fiore VF, Douglas A, Barker TH, Yi H, Wright ER, Crowe JE, Santangelo PJ (2014) ACS Nano 8(1): 302-15
    › Primary publication · 24351207 (PubMed) · PMC3906890 (PubMed Central)
  108. The potent and broadly neutralizing human dengue virus-specific monoclonal antibody 1C19 reveals a unique cross-reactive epitope on the bc loop of domain II of the envelope protein. Smith SA, de Alwis AR, Kose N, Harris E, Ibarra KD, Kahle KM, Pfaff JM, Xiang X, Doranz BJ, de Silva AM, Austin SK, Sukupolvi-Petty S, Diamond MS, Crowe JE (2013) mBio 4(6): e00873-13
    › Primary publication · 24255124 (PubMed) · PMC3870244 (PubMed Central)
  109. Impact of new sequencing technologies on studies of the human B cell repertoire. Finn JA, Crowe JE (2013) Curr Opin Immunol 25(5): 613-8
    › Primary publication · 24161653 (PubMed) · PMC3882336 (PubMed Central)
  110. Gold nanorod vaccine for respiratory syncytial virus. Stone JW, Thornburg NJ, Blum DL, Kuhn SJ, Wright DW, Crowe JE (2013) Nanotechnology 24(29): 295102
    › Primary publication · 23799651 (PubMed) · PMC3754908 (PubMed Central)
  111. Human rotavirus VP6-specific antibodies mediate intracellular neutralization by binding to a quaternary structure in the transcriptional pore. Aiyegbo MS, Sapparapu G, Spiller BW, Eli IM, Williams DR, Kim R, Lee DE, Liu T, Li S, Woods VL, Nannemann DP, Meiler J, Stewart PL, Crowe JE (2013) PLoS One 8(5): e61101
    › Primary publication · 23671563 (PubMed) · PMC3650007 (PubMed Central)
  112. Immunology. Crowdsourcing immunity. Crowe JE (2013) Science 340(6133): 692-3
    › Primary publication · 23661747 (PubMed)
  113. Human germline antibody gene segments encode polyspecific antibodies. Willis JR, Briney BS, DeLuca SL, Crowe JE, Meiler J (2013) PLoS Comput Biol 9(4): e1003045
    › Primary publication · 23637590 (PubMed) · PMC3636087 (PubMed Central)
  114. Discovering naturally processed antigenic determinants that confer protective T cell immunity. Gilchuk P, Spencer CT, Conant SB, Hill T, Gray JJ, Niu X, Zheng M, Erickson JJ, Boyd KL, McAfee KJ, Oseroff C, Hadrup SR, Bennink JR, Hildebrand W, Edwards KM, Crowe JE, Williams JV, Buus S, Sette A, Schumacher TN, Link AJ, Joyce S (2013) J Clin Invest 123(5): 1976-87
    › Primary publication · 23543059 (PubMed) · PMC3635741 (PubMed Central)
  115. Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. Smith SA, de Alwis R, Kose N, Durbin AP, Whitehead SS, de Silva AM, Crowe JE (2013) J Infect Dis 207(12): 1898-908
    › Primary publication · 23526830 (PubMed) · PMC3654755 (PubMed Central)
  116. Reversion of somatic mutations of the respiratory syncytial virus-specific human monoclonal antibody Fab19 reveal a direct relationship between association rate and neutralizing potency. Bates JT, Keefer CJ, Utley TJ, Correia BE, Schief WR, Crowe JE (2013) J Immunol 190(7): 3732-9
    › Primary publication · 23455501 (PubMed) · PMC3608519 (PubMed Central)
  117. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Xu R, Krause JC, McBride R, Paulson JC, Crowe JE, Wilson IA (2013) Nat Struct Mol Biol 20(3): 363-70
    › Primary publication · 23396351 (PubMed) · PMC3594569 (PubMed Central)
  118. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim DH, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE, Piedra PA, Gilbert BE (2013) MAbs 5(2): 263-9
    › Primary publication · 23396091 (PubMed) · PMC3893236 (PubMed Central)
  119. Molecular mechanisms driving respiratory syncytial virus assembly. Shaikh FY, Crowe JE (2013) Future Microbiol 8(1): 123-31
    › Primary publication · 23252497 (PubMed) · PMC3577052 (PubMed Central)
  120. Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE, Wilson IA, Basler CF (2012) PLoS Pathog 8(12): e1003067
    › Primary publication · 23236279 (PubMed) · PMC3516549 (PubMed Central)
  121. Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine. Benhnia MR, Maybeno M, Blum D, Aguilar-Sino R, Matho M, Meng X, Head S, Felgner PL, Zajonc DM, Koriazova L, Kato S, Burton DR, Xiang Y, Crowe JE, Peters B, Crotty S (2013) J Virol 87(3): 1569-85
    › Primary publication · 23152530 (PubMed) · PMC3554146 (PubMed Central)
  122. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival. Engelhardt BG, Sengsayadeth SM, Jagasia M, Savani BN, Kassim AA, Lu P, Shyr Y, Yoder SM, Rock MT, Crowe JE (2012) Exp Hematol 40(12): 974-982.e1
    › Primary publication · 22885125 (PubMed) · PMC3611587 (PubMed Central)
  123. Influenza virus resistance to human neutralizing antibodies. Crowe JE (2012) mBio 3(4): e00213-12
    › Primary publication · 22851660 (PubMed) · PMC3419524 (PubMed Central)
  124. Respiratory syncytial virus assembles into structured filamentous virion particles independently of host cytoskeleton and related proteins. Shaikh FY, Utley TJ, Craven RE, Rogers MC, Lapierre LA, Goldenring JR, Crowe JE (2012) PLoS One 7(7): e40826
    › Primary publication · 22808269 (PubMed) · PMC3396619 (PubMed Central)
  125. Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity. Briney BS, Willis JR, Crowe JE (2012) Genes Immun 13(7): 523-9
    › Primary publication · 22717702 (PubMed) · PMC3449029 (PubMed Central)
  126. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals. Briney BS, Willis JR, McKinney BA, Crowe JE (2012) Genes Immun 13(6): 469-73
    › Primary publication · 22622198 (PubMed)
  127. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire. Briney BS, Willis JR, Hicar MD, Thomas JW, Crowe JE (2012) Immunology 137(1): 56-64
    › Primary publication · 22612413 (PubMed) · PMC3449247 (PubMed Central)
  128. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. Briney BS, Willis JR, Crowe JE (2012) PLoS One 7(5): e36750
    › Primary publication · 22590602 (PubMed) · PMC3348910 (PubMed Central)
  129. Human monoclonal antibodies to pandemic 1957 H2N2 and pandemic 1968 H3N2 influenza viruses. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Albrecht R, Blum DL, Ramos I, Fernandez-Sesma A, Edwards KM, García-Sastre A, Basler CF, Crowe JE (2012) J Virol 86(11): 6334-40
    › Primary publication · 22457520 (PubMed) · PMC3372199 (PubMed Central)
  130. A critical phenylalanine residue in the respiratory syncytial virus fusion protein cytoplasmic tail mediates assembly of internal viral proteins into viral filaments and particles. Shaikh FY, Cox RG, Lifland AW, Hotard AL, Williams JV, Moore ML, Santangelo PJ, Crowe JE (2012) mBio 3(1)
    › Primary publication · 22318318 (PubMed) · PMC3280462 (PubMed Central)
  131. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity. Engelhardt BG, Jagasia SM, Crowe JE, Griffith ML, Savani BN, Kassim AA, Lu P, Weitkamp JH, Moore DJ, Yoder SM, Rock MT, Jagasia M (2012) Blood 119(10): 2417-21
    › Primary publication · 22262764 (PubMed) · PMC3311262 (PubMed Central)
  132. Persistence of circulating memory B cell clones with potential for dengue virus disease enhancement for decades following infection. Smith SA, Zhou Y, Olivarez NP, Broadwater AH, de Silva AM, Crowe JE (2012) J Virol 86(5): 2665-75
    › Primary publication · 22171265 (PubMed) · PMC3302281 (PubMed Central)
  133. Maturation-induced cloaking of neutralization epitopes on HIV-1 particles. Joyner AS, Willis JR, Crowe JE, Aiken C (2011) PLoS Pathog 7(9): e1002234
    › Primary publication · 21931551 (PubMed) · PMC3169560 (PubMed Central)
  134. Epitope-specific human influenza antibody repertoires diversify by B cell intraclonal sequence divergence and interclonal convergence. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Briney BS, Smith SA, Basler CF, Crowe JE (2011) J Immunol 187(7): 3704-11
    › Primary publication · 21880983 (PubMed) · PMC3178754 (PubMed Central)
  135. Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays. Rock MT, McKinney BA, Yoder SM, Prudom CE, Wright DW, Crowe JE (2011) J Immunol Methods 374(1-2): 13-7
    › Primary publication · 21854782 (PubMed) · PMC3220792 (PubMed Central)
  136. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. Krause JC, Tsibane T, Tumpey TM, Huffman CJ, Basler CF, Crowe JE (2011) J Virol 85(20): 10905-8
    › Primary publication · 21849447 (PubMed) · PMC3187471 (PubMed Central)
  137. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication. Lindquist ME, Mainou BA, Dermody TS, Crowe JE (2011) Virology 413(1): 103-10
    › Primary publication · 21377708 (PubMed) · PMC3072468 (PubMed Central)
  138. An insertion mutation that distorts antibody binding site architecture enhances function of a human antibody. Krause JC, Ekiert DC, Tumpey TM, Smith PB, Wilson IA, Crowe JE (2011) mBio 2(1): e00345-10
    › Primary publication · 21304166 (PubMed) · PMC3037006 (PubMed Central)
  139. Specificity for human hemoglobin enhances Staphylococcus aureus infection. Pishchany G, McCoy AL, Torres VJ, Krause JC, Crowe JE, Fabry ME, Skaar EP (2010) Cell Host Microbe 8(6): 544-50
    › Primary publication · 21147468 (PubMed) · PMC3032424 (PubMed Central)
  140. Transforming growth factor beta is a major regulator of human neonatal immune responses following respiratory syncytial virus infection. Thornburg NJ, Shepherd B, Crowe JE (2010) J Virol 84(24): 12895-902
    › Primary publication · 20926560 (PubMed) · PMC3004333 (PubMed Central)
  141. Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE (2010) J Virol 84(23): 12274-84
    › Primary publication · 20844027 (PubMed) · PMC2976418 (PubMed Central)
  142. Regulatory T cell expression of CLA or α(4)β(7) and skin or gut acute GVHD outcomes. Engelhardt BG, Jagasia M, Savani BN, Bratcher NL, Greer JP, Jiang A, Kassim AA, Lu P, Schuening F, Yoder SM, Rock MT, Crowe JE (2011) Bone Marrow Transplant 46(3): 436-42
    › Primary publication · 20577222 (PubMed) · PMC3217583 (PubMed Central)
  143. Homing in on acute graft vs. host disease: tissue-specific T regulatory and Th17 cells. Engelhardt BG, Crowe JE (2010) Curr Top Microbiol Immunol : 121-46
    › Primary publication · 20563712 (PubMed) · PMC3793903 (PubMed Central)
  144. Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV. Hicar MD, Chen X, Briney B, Hammonds J, Wang JJ, Kalams S, Spearman PW, Crowe JE (2010) J Acquir Immune Defic Syndr 54(3): 223-35
    › Primary publication · 20531016 (PubMed) · PMC2930513 (PubMed Central)
  145. Emerging studies of human HIV-specific antibody repertoires. Hicar MD, Kalams SA, Spearman PW, Crowe JE (2010) Vaccine : B18-23
    › Primary publication · 20510738 (PubMed) · PMC2879399 (PubMed Central)
  146. Population-based incidence of human metapneumovirus infection among hospitalized children. Williams JV, Edwards KM, Weinberg GA, Griffin MR, Hall CB, Zhu Y, Szilagyi PG, Wang CK, Yang CF, Silva D, Ye D, Spaete RR, Crowe JE (2010) J Infect Dis 201(12): 1890-8
    › Primary publication · 20446850 (PubMed) · PMC2873123 (PubMed Central)
  147. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. Krause JC, Tumpey TM, Huffman CJ, McGraw PA, Pearce MB, Tsibane T, Hai R, Basler CF, Crowe JE (2010) J Virol 84(6): 3127-30
    › Primary publication · 20042511 (PubMed) · PMC2826039 (PubMed Central)
  148. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches. Crowe JE (2009) Vaccine : G47-51
    › Primary publication · 20006140 (PubMed) · PMC2835990 (PubMed Central)
  149. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years. Yang CF, Wang CK, Tollefson SJ, Piyaratna R, Lintao LD, Chu M, Liem A, Mark M, Spaete RR, Crowe JE, Williams JV (2009) Virol J : 138
    › Primary publication · 19740442 (PubMed) · PMC2753315 (PubMed Central)
  150. The pediatric burden of human coronaviruses evaluated for twenty years. Talbot HK, Shepherd BE, Crowe JE, Griffin MR, Edwards KM, Podsiad AB, Tollefson SJ, Wright PF, Williams JV (2009) Pediatr Infect Dis J 28(8): 682-7
    › Primary publication · 19633513 (PubMed) · PMC2765860 (PubMed Central)
  151. Coronavirus infection and hospitalizations for acute respiratory illness in young children. Talbot HK, Crowe JE, Edwards KM, Griffin MR, Zhu Y, Weinberg GA, Szilagyi PG, Hall CB, Podsiad AB, Iwane M, Williams JV, New Vaccine Surveillance Network (2009) J Med Virol 81(5): 853-6
    › Primary publication · 19319948 (PubMed) · PMC2767383 (PubMed Central)
  152. A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. Moore ML, Chi MH, Luongo C, Lukacs NW, Polosukhin VV, Huckabee MM, Newcomb DC, Buchholz UJ, Crowe JE, Goleniewska K, Williams JV, Collins PL, Peebles RS (2009) J Virol 83(9): 4185-94
    › Primary publication · 19211758 (PubMed) · PMC2668460 (PubMed Central)
  153. Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation. Derdowski A, Peters TR, Glover N, Qian R, Utley TJ, Burnett A, Williams JV, Spearman P, Crowe JE (2008) J Gen Virol 89(Pt 11): 2698-2708
    › Primary publication · 18931065 (PubMed) · PMC2876975 (PubMed Central)
  154. An alphavirus replicon-based human metapneumovirus vaccine is immunogenic and protective in mice and cotton rats. Mok H, Tollefson SJ, Podsiad AB, Shepherd BE, Polosukhin VV, Johnston RE, Williams JV, Crowe JE (2008) J Virol 82(22): 11410-8
    › Primary publication · 18786987 (PubMed) · PMC2573258 (PubMed Central)
  155. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Yu X, Tsibane T, McGraw PA, House FS, Keefer CJ, Hicar MD, Tumpey TM, Pappas C, Perrone LA, Martinez O, Stevens J, Wilson IA, Aguilar PV, Altschuler EL, Basler CF, Crowe JE (2008) Nature 455(7212): 532-6
    › Primary publication · 18716625 (PubMed) · PMC2848880 (PubMed Central)
  156. Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope. Mok H, Lee S, Wright DW, Crowe JE (2008) Vaccine 26(37): 4775-82
    › Primary publication · 18662734 (PubMed) · PMC2561208 (PubMed Central)
  157. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2. Utley TJ, Ducharme NA, Varthakavi V, Shepherd BE, Santangelo PJ, Lindquist ME, Goldenring JR, Crowe JE (2008) Proc Natl Acad Sci U S A 105(29): 10209-14
    › Primary publication · 18621683 (PubMed) · PMC2481327 (PubMed Central)
  158. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies. Yu X, McGraw PA, House FS, Crowe JE (2008) J Immunol Methods 336(2): 142-51
    › Primary publication · 18514220 (PubMed) · PMC2519117 (PubMed Central)
  159. Functional maturation of the human antibody response to rotavirus. Kallewaard NL, McKinney BA, Gu Y, Chen A, Prasad BV, Crowe JE (2008) J Immunol 180(6): 3980-9
    › Primary publication · 18322207 (PubMed)
  160. Immunodominance of the VH1-46 antibody gene segment in the primary repertoire of human rotavirus-specific B cells is reduced in the memory compartment through somatic mutation of nondominant clones. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE (2008) J Immunol 180(5): 3279-88
    › Primary publication · 18292552 (PubMed)
  161. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. Mok H, Lee S, Utley TJ, Shepherd BE, Polosukhin VV, Collier ML, Davis NL, Johnston RE, Crowe JE (2007) J Virol 81(24): 13710-22
    › Primary publication · 17928349 (PubMed) · PMC2168850 (PubMed Central)
  162. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE, Williamson RA (2007) J Virol 81(15): 8315-24
    › Primary publication · 17522220 (PubMed) · PMC1951312 (PubMed Central)
  163. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naïve and memory B cells. Tian C, Luskin GK, Dischert KM, Higginbotham JN, Shepherd BE, Crowe JE (2007) Mol Immunol 44(9): 2173-83
    › Primary publication · 17196657 (PubMed) · PMC1859862 (PubMed Central)
  164. Tissue-specific regulation of CD8+ T-lymphocyte immunodominance in respiratory syncytial virus infection. Lee S, Miller SA, Wright DW, Rock MT, Crowe JE (2007) J Virol 81(5): 2349-58
    › Primary publication · 17182672 (PubMed) · PMC1865932 (PubMed Central)
  165. Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. Miller SA, Tollefson S, Crowe JE, Williams JV, Wright DW (2007) J Virol 81(1): 141-9
    › Primary publication · 17035305 (PubMed) · PMC1797239 (PubMed Central)
  166. Cytokine expression patterns associated with systemic adverse events following smallpox immunization. McKinney BA, Reif DM, Rock MT, Edwards KM, Kingsmore SF, Moore JH, Crowe JE (2006) J Infect Dis 194(4): 444-53
    › Primary publication · 16845627 (PubMed) · PMC1620015 (PubMed Central)
  167. Cellular immune responses to diluted and undiluted aventis pasteur smallpox vaccine. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE (2006) J Infect Dis 194(4): 435-43
    › Primary publication · 16845626 (PubMed)
  168. Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells. Tian C, Kron GK, Dischert KM, Higginbotham JN, Crowe JE (2006) Immunology 119(1): 54-62
    › Primary publication · 16764687 (PubMed) · PMC1782340 (PubMed Central)
  169. Transcriptional control of activation-induced cytidine deaminase and error-prone DNA polymerases is functionally mature in the B cells of infants at birth. Bowen AL, Tian C, LaFleur BJ, Crowe JE (2006) Hum Immunol 67(1-2): 43-6
    › Primary publication · 16698424 (PubMed)
  170. Rotavirus-specific CD5+ B cells in young children exhibit a distinct antibody repertoire compared with CD5- B cells. Weitkamp JH, Lafleur BJ, Crowe JE (2006) Hum Immunol 67(1-2): 33-42
    › Primary publication · 16698423 (PubMed)
  171. Hybrid grammar-based approach to nonlinear dynamical system identification from biological time series. McKinney BA, Crowe JE, Voss HU, Crooke PS, Barney N, Moore JH (2006) Phys Rev E Stat Nonlin Soft Matter Phys 73(2 Pt 1): 021912
    › Primary publication · 16605367 (PubMed)
  172. The role of human metapneumovirus in upper respiratory tract infections in children: a 20-year experience. Williams JV, Wang CK, Yang CF, Tollefson SJ, House FS, Heck JM, Chu M, Brown JB, Lintao LD, Quinto JD, Chu D, Spaete RR, Edwards KM, Wright PF, Crowe JE (2006) J Infect Dis 193(3): 387-95
    › Primary publication · 16388486 (PubMed) · PMC1586246 (PubMed Central)
  173. The transmembrane domain of the respiratory syncytial virus F protein is an orientation-independent apical plasma membrane sorting sequence. Brock SC, Heck JM, McGraw PA, Crowe JE (2005) J Virol 79(19): 12528-35
    › Primary publication · 16160180 (PubMed) · PMC1211512 (PubMed Central)
  174. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. Williams JV, Crowe JE, Enriquez R, Minton P, Peebles RS, Hamilton RG, Higgins S, Griffin M, Hartert TV (2005) J Infect Dis 192(7): 1149-53
    › Primary publication · 16136455 (PubMed) · PMC1476781 (PubMed Central)
  175. A prospective study comparing human metapneumovirus with other respiratory viruses in adults with hematologic malignancies and respiratory tract infections. Williams JV, Martino R, Rabella N, Otegui M, Parody R, Heck JM, Crowe JE (2005) J Infect Dis 192(6): 1061-5
    › Primary publication · 16107960 (PubMed) · PMC1483060 (PubMed Central)
  176. The cotton rat (Sigmodon hispidus) is a permissive small animal model of human metapneumovirus infection, pathogenesis, and protective immunity. Williams JV, Tollefson SJ, Johnson JE, Crowe JE (2005) J Virol 79(17): 10944-51
    › Primary publication · 16103146 (PubMed) · PMC1193579 (PubMed Central)
  177. Natural evolution of a human virus-specific antibody gene repertoire by somatic hypermutation requires both hotspot-directed and randomly-directed processes. Weitkamp JH, Lafleur BJ, Greenberg HB, Crowe JE (2005) Hum Immunol 66(6): 666-76
    › Primary publication · 15993712 (PubMed)
  178. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. Chen X, Rock MT, Hammonds J, Tartaglia J, Shintani A, Currier J, Slike B, Crowe JE, Marovich M, Spearman P (2005) J Virol 79(9): 5537-47
    › Primary publication · 15827168 (PubMed) · PMC1082749 (PubMed Central)
  179. Progression of respiratory syncytial virus infection monitored by fluorescent quantum dot probes. Bentzen EL, House F, Utley TJ, Crowe JE, Wright DW (2005) Nano Lett 5(4): 591-5
    › Primary publication · 15826092 (PubMed)
  180. Prevalence of reovirus-specific antibodies in young children in Nashville, Tennessee. Tai JH, Williams JV, Edwards KM, Wright PF, Crowe JE, Dermody TS (2005) J Infect Dis 191(8): 1221-4
    › Primary publication · 15776366 (PubMed) · PMC7109872 (PubMed Central)
  181. Differential regulation of granzyme and perforin in effector and memory T cells following smallpox immunization. Rock MT, Yoder SM, Wright PF, Talbot TR, Edwards KM, Crowe JE (2005) J Immunol 174(6): 3757-64
    › Primary publication · 15749916 (PubMed)
  182. VH1-46 is the dominant immunoglobulin heavy chain gene segment in rotavirus-specific memory B cells expressing the intestinal homing receptor alpha4beta7. Weitkamp JH, Kallewaard NL, Bowen AL, Lafleur BJ, Greenberg HB, Crowe JE (2005) J Immunol 174(6): 3454-60
    › Primary publication · 15749880 (PubMed)
  183. Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus. Kallewaard NL, Bowen AL, Crowe JE (2005) Virology 331(1): 73-81
    › Primary publication · 15582654 (PubMed)
  184. Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: a randomized controlled trial. Talbot TR, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, Yoder SM, Rock MT, Crowe JE, Edwards KM (2004) JAMA 292(10): 1205-12
    › Primary publication · 15353533 (PubMed)
  185. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe JE (2004) J Infect Dis 189(8): 1401-10
    › Primary publication · 15073677 (PubMed)
  186. Effect of zinc salts on respiratory syncytial virus replication. Suara RO, Crowe JE (2004) Antimicrob Agents Chemother 48(3): 783-90
    › Primary publication · 14982765 (PubMed) · PMC353050 (PubMed Central)
  187. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, Crowe JE (2004) N Engl J Med 350(5): 443-50
    › Primary publication · 14749452 (PubMed) · PMC1831873 (PubMed Central)
  188. Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells. Brock SC, Goldenring JR, Crowe JE (2003) Proc Natl Acad Sci U S A 100(25): 15143-8
    › Primary publication · 14630951 (PubMed) · PMC299925 (PubMed Central)
  189. Fatal hemophagocytic lymphohistiocytosis associated with Epstein-Barr virus infection in a patient with a novel mutation in the signaling lymphocytic activation molecule-associated protein. Halasa NB, Whitlock JA, McCurley TL, Smith JA, Zhu Q, Ochs H, Dermody TS, Crowe JE (2003) Clin Infect Dis 37(10): e136-41
    › Primary publication · 14583885 (PubMed)
  190. Infant and adult human B cell responses to rotavirus share common immunodominant variable gene repertoires. Weitkamp JH, Kallewaard N, Kusuhara K, Bures E, Williams JV, LaFleur B, Greenberg HB, Crowe JE (2003) J Immunol 171(9): 4680-8
    › Primary publication · 14568943 (PubMed)
  191. CD154 regulates primate humoral immunity to influenza. Crowe JE, Sannella EC, Pfeiffer S, Zorn GL, Azimzadeh A, Newman R, Miller GG, Pierson RN (2003) Am J Transplant 3(6): 680-8
    › Primary publication · 12780559 (PubMed)
  192. Immunology of viral respiratory tract infection in infancy. Crowe JE, Williams JV (2003) Paediatr Respir Rev 4(2): 112-9
    › Primary publication · 12758048 (PubMed)
  193. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles. Weitkamp JH, Kallewaard N, Kusuhara K, Feigelstock D, Feng N, Greenberg HB, Crowe JE (2003) J Immunol Methods 275(1-2): 223-37
    › Primary publication · 12667686 (PubMed)
  194. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. Rock MT, Crowe JE (2003) Immunology 108(4): 474-80
    › Primary publication · 12667209 (PubMed) · PMC1782928 (PubMed Central)
  195. The human polymeric immunoglobulin receptor facilitates invasion of epithelial cells by Streptococcus pneumoniae in a strain-specific and cell type-specific manner. Brock SC, McGraw PA, Wright PF, Crowe JE (2002) Infect Immun 70(9): 5091-5
    › Primary publication · 12183558 (PubMed) · PMC128237 (PubMed Central)
  196. Pneumocystis carinii pneumonia in a girl with a midbrain glioma. Peters TR, Jennings MT, Crowe JE (2002) Pediatr Hematol Oncol 19(2): 141-3
    › Primary publication · 11881789 (PubMed)
  197. Influence of maternal antibodies on neonatal immunization against respiratory viruses. Crowe JE (2001) Clin Infect Dis 33(10): 1720-7
    › Primary publication · 11595986 (PubMed)
  198. Respiratory syncytial virus vaccine development. Crowe JE (2001) Vaccine : S32-7
    › Primary publication · 11587807 (PubMed)
  199. Blood donor leukocyte reduction filters as a source of human B lymphocytes. Weitkamp JH, Crowe JE (2001) Biotechniques 31(3): 464, 466
    › Primary publication · 11570486 (PubMed)
  200. Passively acquired antibodies suppress humoral but not cell-mediated immunity in mice immunized with live attenuated respiratory syncytial virus vaccines. Crowe JE, Firestone CY, Murphy BR (2001) J Immunol 167(7): 3910-8
    › Primary publication · 11564809 (PubMed)
  201. CD40-ligand in primate cardiac allograft and viral immunity. Pierson RN, Crowe JE, Pfeiffer S, Atkinson J, Azimzadeh A, Miller GG (2001) Immunol Res 23(2-3): 253-62
    › Primary publication · 11444390 (PubMed)
  202. Genetic and structural determinants of virus neutralizing antibodies. Crowe JE, Suara RO, Brock S, Kallewaard N, House F, Weitkamp JH (2001) Immunol Res 23(2-3): 135-45
    › Primary publication · 11444379 (PubMed)
  203. Recurrent pneumococcal arthritis as the presenting manifestation of X-linked agammaglobulinemia. Peters TR, Brumbaugh DE, Lawton AR, Crowe JE (2000) Clin Infect Dis 31(5): 1287-8
    › Primary publication · 11073766 (PubMed)
  204. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR (2000) J Infect Dis 182(5): 1331-42
    › Primary publication · 11010838 (PubMed)
  205. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Pastey MK, Gower TL, Spearman PW, Crowe JE, Graham BS (2000) Nat Med 6(1): 35-40
    › Primary publication · 10613821 (PubMed) · PMC7095870 (PubMed Central)
  206. RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Pastey MK, Crowe JE, Graham BS (1999) J Virol 73(9): 7262-70
    › Primary publication · 10438814 (PubMed) · PMC104251 (PubMed Central)
  207. Host responses to respiratory virus infection and immunization. Crowe JE (1999) Curr Top Microbiol Immunol : 191-214
    › Primary publication · 9893361 (PubMed)
  208. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines. Crowe JE (1998) Vaccine 16(14-15): 1423-32
    › Primary publication · 9711783 (PubMed)